2-Pyrrolidinone, 1-[(4-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)-1-piperidinyl]-, (3R)- manufacturers
- BMT-108908
-
- $3400.00
-
2026-05-11
- CAS:1801151-15-4
- Purity:
- Supply Ability: 10g
|
| | 2-Pyrrolidinone, 1-[(4-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)-1-piperidinyl]-, (3R)- Basic information |
| | 2-Pyrrolidinone, 1-[(4-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)-1-piperidinyl]-, (3R)- Chemical Properties |
| Boiling point | 570.6±50.0 °C(Predicted) | | density | 1.259±0.06 g/cm3(Predicted) | | pka | 10.15±0.30(Predicted) |
| | 2-Pyrrolidinone, 1-[(4-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)-1-piperidinyl]-, (3R)- Usage And Synthesis |
| Description | BMT-108908 is a Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains. BMT-108908 displayed potent rat GluN2B binding adjunctive therapy for TRD has demonstrated a 60% response rate, with 78% of responders having maintained a response for at least 1 week. | | Uses | BMT-108908 is a negative allosteric modulator with selective activity on the NR2B subtype of the NMDA receptor. BMT-108908 has been shown to damage cognition in research, affecting cognitive functions in multiple areas. BMT-108908 failed to show a significant impact on the γ wave power of the EEG in the experiment, but it had a significant inhibitory and enhancement effect on the β wave and δ wave power[1]. | | References | [1] The qEEG Signature of Selective NMDA NR2B Negative Allosteric Modulators; A Potential Translational Biomarker for Drug Development DOI:10.1371/journal.pone.0152729 |
| | 2-Pyrrolidinone, 1-[(4-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)-1-piperidinyl]-, (3R)- Preparation Products And Raw materials |
|